This Reopening Stock Has A Better 1-Year Return Than Moderna, Pfizer, BioNTech, Novavax And Vaxart

Macy's Inc M retail stores have something for everyone in the family, and over the past year, has returned unmistakable gains for bullish traders and investors.

Since February 2021, Macy’s stock’s one-year return has outperformed several of the world’s most popular vaccine stocks: Moderna Inc MRNA, Pfizer Inc. PFE, BioNTech SE - ADR BNTX, Novavax, Inc. NVAX and Vaxart Inc VXRT.

Founded in 1858, Macy's operates nearly 600 stores as the Macy's brand, 58 stores as the Bloomingdale's brand and 160 freestanding Bluemercury specialty beauty stores.

Macy's also operates e-commerce sites, owns 65% of a Chinese e-commerce joint venture, and licenses two Bloomingdale's stores in the United Arab Emirates and Kuwait. Women's apparel, accessories, shoes, cosmetics, and fragrances make up a majority of Macy’s sales. 

Here's how the returns break down from February 2021 to present: 

• Novavax is down from $273.98 to $86.55 for a return of -68.41%
• Vaxart is down from $7.94 to $5.04 for a return of -36.52%
• Moderna is down from $176.76 to $151.81 for a return of -14.12%
• Pfizer is up from $34.89 to $49.68 for a return of 42.39%
• BioNTech is up from $113.56 to $165.49 for a return of 45.73%
• And finally, Macy’s is up from $14.70 to $26.11 for a return of 77.62%.